How many shares did Inogen repurchase and at what cost?

Inogen repurchased 1,145,150 shares in the first half of 2026 for $7.5 million, or approximately $6.55 per share. The company announced this repurchase program in Q1 2026 and has been executing purchases under its authorization throughout the first six months of the year.

What does this buyback mean for Inogen's share count?

The repurchase reduces Inogen's share count by approximately 4.2% (based on 27.0 million weighted-average basic shares outstanding in H1 2026). While modest in percentage terms, this reduction could provide accretion to future earnings per share if the company achieves profitability, though the company currently reports GAAP net losses.

How does Inogen's cash position support the buyback?

Inogen held $106.8 million in cash, cash equivalents, marketable securities, and restricted cash as of June 30, 2026, with no debt. The $7.5 million deployed for buybacks represents 7% of available liquidity, demonstrating conservative capital allocation while maintaining a strong balance sheet.

Was Inogen profitable when it authorized this repurchase program?

No. Inogen reported a GAAP net loss of $12.2 million in H1 2026 and is not currently GAAP-profitable. However, the company reported positive adjusted EBITDA of $2.4 million in Q2 2026 and raised full-year 2026 adjusted EBITDA guidance to $4.0 million, suggesting improving operational leverage.

What execution mechanism does Inogen use for repurchases?

The filing does not specify the repurchase mechanism (e.g., open-market Rule 10b-18 purchases, 10b5-1 plan, or ASR). Inogen disclosed only the aggregate shares repurchased and total cost; the method of execution is not disclosed in this earnings announcement.

Is there remaining authorization for future repurchases?

The filing does not disclose the original authorization amount or remaining authorization under the Q1 2026 repurchase program. Only the execution to date (1.1 million shares, $7.5 million) is reported in this earnings announcement.

INGN 8-K Filed 2026-08-06 Execution disclosure

Inogen repurchased 1.1M shares for $7.5M in first half 2026

Medical device company reports progress on share buyback announced in Q1 2026 under ongoing repurchase program

Shares repurchased1.1M

Avg price paid$6.55

MechanismNot specified

What the filing says

Inogen Inc. (Nasdaq: INGN) reported execution of its share repurchase program during the first half of 2026, repurchasing 1,145,150 shares of common stock for a total consideration of $7.5 million. The company announced the program in the first quarter of 2026 and has been executing purchases under its authorization.

As of June 30, 2026, Inogen held cash, cash equivalents, marketable securities, and restricted cash totaling $106.8 million with no debt outstanding. The company's balance sheet remained strong despite the repurchase activity and ongoing investments in product development and international expansion, including new product launches and clinical studies to support long-term growth.

The repurchase program reflects management's confidence in long-term shareholder value creation amid improving operational trends, including positive adjusted EBITDA of $2.4 million in Q2 2026 and raised full-year 2026 adjusted EBITDA guidance to approximately $4.0 million, representing 48.1% growth over 2025.

The Company repurchased 1,145,150 shares of its common stock in the first half of 2026 for consideration of $7.5 million under the share repurchase program that was announced in the first quarter of 2026. — Inogen Inc 8-K filing · View on SEC EDGAR →

What this means

Inogen executed 1.1 million share repurchases at an average price of approximately $6.55 per share during H1 2026, totaling $7.5 million. This represents modest capital deployment relative to the company's $106.8 million cash position and ongoing net losses (GAAP net loss of $12.2 million for H1 2026). The buyback reduces share count by roughly 4.2%, which could provide modest accretion to future per-share metrics if the company returns to profitability. The execution demonstrates management prioritization of shareholder returns despite near-term profitability challenges, balanced against investment in product innovation and international market expansion.

Frequently asked questions

How many shares did Inogen repurchase and at what cost?: Inogen repurchased 1,145,150 shares in the first half of 2026 for $7.5 million, or approximately $6.55 per share. The company announced this repurchase program in Q1 2026 and has been executing purchases under its authorization throughout the first six months of the year.
What does this buyback mean for Inogen's share count?: The repurchase reduces Inogen's share count by approximately 4.2% (based on 27.0 million weighted-average basic shares outstanding in H1 2026). While modest in percentage terms, this reduction could provide accretion to future earnings per share if the company achieves profitability, though the company currently reports GAAP net losses.
How does Inogen's cash position support the buyback?: Inogen held $106.8 million in cash, cash equivalents, marketable securities, and restricted cash as of June 30, 2026, with no debt. The $7.5 million deployed for buybacks represents 7% of available liquidity, demonstrating conservative capital allocation while maintaining a strong balance sheet.
Was Inogen profitable when it authorized this repurchase program?: No. Inogen reported a GAAP net loss of $12.2 million in H1 2026 and is not currently GAAP-profitable. However, the company reported positive adjusted EBITDA of $2.4 million in Q2 2026 and raised full-year 2026 adjusted EBITDA guidance to $4.0 million, suggesting improving operational leverage.
What execution mechanism does Inogen use for repurchases?: The filing does not specify the repurchase mechanism (e.g., open-market Rule 10b-18 purchases, 10b5-1 plan, or ASR). Inogen disclosed only the aggregate shares repurchased and total cost; the method of execution is not disclosed in this earnings announcement.
Is there remaining authorization for future repurchases?: The filing does not disclose the original authorization amount or remaining authorization under the Q1 2026 repurchase program. Only the execution to date (1.1 million shares, $7.5 million) is reported in this earnings announcement.

execution medical-device mid-cap rule-10b-18 cash-return

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.